We are live on ! Find out more
IONS icon

Ionis Pharmaceuticals

204 hedge funds and large institutions have $3.91B invested in Ionis Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 61 increasing their positions, 75 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

254% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 13

67% more funds holding in top 10

Funds holding in top 10: 35 (+2)

38% more capital invested

Capital invested by funds: $2.84B → $3.91B (+$1.07B)

18% more funds holding

Funds holding: 173204 (+31)

19% less repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 75

31% less call options, than puts

Call options by funds: $40.4M | Put options by funds: $58.5M

Holders
204
Holders Change
+31
Holders Change %
+17.92%
% of All Funds
6.61%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.16%
New
46
Increased
61
Reduced
75
Closed
13
Calls
$40.4M
Puts
$58.5M
Net Calls
-$18M
Net Calls Change
-$24.6M
Name Holding Trade Value Shares
Change
Change in
Stake
CAM
151
Capstone Asset Management
Texas
$450K -$2.99K -100 -0.8%
AT
152
Arden Trust
Delaware
$440K -$564K -18,895 -62%
SM
153
Sabby Management
Florida
$438K +$348K +11,663 New
FAM
154
Fortaleza Asset Management
Illinois
$429K +$342K +11,435 New
QIM
155
Quest Investment Management
Oregon
$402K -$40.8K -1,365 -11%
AC
156
Alexandria Capital
Virginia
$375K
RCM
157
Reynolds Capital Management
Nevada
$372K +$296K +9,900 New
AIP
158
Ameritas Investment Partners
Nebraska
$364K +$289K +9,685 New
SB
159
Suntrust Banks
Georgia
$361K -$1.2K -40 -0.4%
TRCT
160
Tower Research Capital (TRC)
New York
$334K +$161K +5,389 +154%
ST
161
Spot Trading
Illinois
$332K -$130K -4,336 -33%
WAM
162
World Asset Management
Michigan
$324K -$51.4K -1,722 -17%
US Bancorp
163
US Bancorp
Minnesota
$320K +$161K +5,398 +173%
Ameriprise
164
Ameriprise
Minnesota
$302K -$6.27K -210 -3%
DC
165
Deere & Company
Illinois
$289K +$230K +7,691 New
CEP
166
Chicago Equity Partners
Illinois
$283K
BJ
167
BlackRock Japan
Japan
$274K -$439K -14,700 -67%
PCM
168
Prelude Capital Management
New York
$268K -$235K -7,874 -52%
V
169
Veritable
Delaware
$253K +$202K +6,748 New
WCM Investment Management
170
WCM Investment Management
California
$221K +$176K +5,900 New
NPC
171
National Planning Corporation
California
$218K +$170K +5,700 New
LTFS
172
Ladenburg Thalmann Financial Services
Florida
$215K -$568 -19 -0.3%
EWM
173
Elite Wealth Management
Washington
$210K +$167K +5,600 New
ACI
174
AMP Capital Investors
Australia
$209K +$163K +5,445 New
William Blair & Company
175
William Blair & Company
Illinois
$208K +$166K +5,547 New

IONS Hedge Fund Activity: Q3 2013 in Review

204 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q3 2013, worth a combined $3.91B — up 38% from $2.84B a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new IONS positions and 13 closed out — a net gain of 33 holders — while 61 added to existing stakes and 75 trimmed.

The largest buyer was Artisan Partners, adding an estimated $43.9M. The largest seller was BNP Paribas Financial Markets, cutting an estimated $29.9M.

  • 204 institutional investors held Ionis Pharmaceuticals (IONS) as of Q3 2013, up from 173 in Q2 2013.
  • Funds reported $3.91B of Ionis Pharmaceuticals stock for Q3 2013, up 38% quarter-over-quarter.
  • 46 funds opened new Ionis Pharmaceuticals positions in Q3 2013 and 13 closed out, a net change of +33 holders.
  • The largest Ionis Pharmaceuticals buyer in Q3 2013 was Artisan Partners, an estimated $43.9M added.
  • The largest Ionis Pharmaceuticals seller in Q3 2013 was BNP Paribas Financial Markets, an estimated $29.9M sold.

Based on aggregated 13F filings for Q3 2013.